SRF Ltd.’s revenue in Q3FY23 rose 4% to ₹ 3,470 crores. Consolidated Profit After Tax came at ₹ 511 crores showcasing a 1% rise YoY over the corresponding period. In this quarter’s results, it is observed that PBT has decreased and PAT has increased due to the reduction in tax expenses.
SRF Limited Q3FY23; 1% Growth in Profits

Tags: Chemicals
Related Post
- Aurobindo Pharma Ltd Q4FY25; 0% fall in Profits
Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals…
-
Astral Ltd Q4FY25; 2% fall in Profits
Astral Poly Technik Ltd was established in 1996, with the aim to manufacture pro-India plumbing…
-
Astrazeneca Pharma India Ltd Q4FY25; 3% rise in Revenue
AstraZeneca Pharma India Ltd is engaged in the business of manufacture, distribution and marketing of…